|
TRAC Portfolio - Silamed, Inc. |
 |
|
|
|
|
Silamed, Inc. (Scottsdale, Arizona) is developing novel small-molecule therapeutics to treat cancer, inflammatory, neurological and fibrosis-associated diseases. Silamed applies cutting edge organosilicon medicinal chemistry to improve the efficacy and safety of known and approved drugs, generating entirely new composition of matter intellectual property and a portfolio of exciting molecules. Silamed’s lead product is currently progressing through IND-enabling studies and is a potent inhibitor of hypoxia-inducible factor-1 (Hif-1).
www.silamed.com |
Date:
December 20, 2007 |
Stage:
Seed |
| |
| |
|
|
|
| |
|
|
|
| |
